TORONTO, Nov 17, 2004 (CCNMatthews via COMTEX)
Biovail Corporation (NYSE:BVF)(TSX:BVF) today confirmed that it has received notification that an abbreviated new drug application (ANDA) has been submitted to the U.S. lasix. Food and Drug Administration (FDA) by Anchen Pharmaceuticals, Inc., seeking marketing approval for 150mg and 300mg generic formulations of Wellbutrin XL(R) (once-daily bupropion). At the present time, it is not known if the ANDA submission has been accepted for review by the FDA.
Most Popular
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking
Public Speaking: 7 Secrets Of Great Public Speakers
13 Job Interview Mistakes To Avoid
3 Questions No Job Seeker Ever Wants To Be Asked?
In accordance with the relevant regulations, Biovail has a 45-day period in which to …
Read the rest of this article with a Free Trial at HighBeam Research.